Clinical Trials
Top 5 Ways Integrated Drug Development Solutions Save You Time and Money
Since 2004, the average cost of bringing a new drug to market has increased from $800 million to about $2.6 billion, without, for the most part, shorter development time
Get to Know Canada’s Best Retinal Specialist and Principal Investigator
Altasciences Ophthalmic Clinical Offering: A Unique Integration of Expertise, Location, and Passion
At Altasciences, we understand the unique challenges of developing treatments for retinal disease. That's why we've created an integrated approach that brings together clinical and scientific expertise specific to ophthalmology. From our state-of-the-art equipment, streamlined processes, to a co-located ophthalmic clinic, every element of our offering is designed to help move treatments forward and improve patient outcomes.
Watch as Dr. William Foster, Retinal Specialist and Principal Investigator, explains why Altasciences is the ideal partner for your ophthalmic clinical trials.
Speak with our experts to discuss your ophthalmic drug development needs.
Have five minutes? Take a look at these resources:
Webpages:
• End-To-End Ophthalmic Drug Development Services
• Clinical Research Services
Scientific Journal: Navigating the Complexities of Ophthalmic Drug Development
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.
Drug Development Timelines: How Health Canada’s 30-Day Regulatory Review Process Could Provide an Advantage
We want novel therapies to be approved fast, while being safe for us. Regulatory agencies around the world strive to balance the critical elements of speed and safety; at the same time, a rigorous review process is a must.
Get the Facts: NDA-Enabling Studies
We’ve Got Your NDA Study Needs Covered
The development of an NDA submission plan can sometimes be unclear. Partnering with the right CRO early on can increase your chances of success and ensure you meet your milestones. With over 25 years of experience across the spectrum of therapeutic areas, Altasciences' specialists apply their knowledge in designing, conducting, analyzing, and reporting on trials for regulatory submissions.
Our complimentary fact sheet guides you through the different types and features of NDA-enabling clinical pharmacology studies, and how we can support you.
Want to learn more about the requirements for each study? Explore these insightful resources:
Your Expert Guide to Developing Psychoactive Substances
Practical Approaches to Conducting
Early Clinical Trials with Psychedelics
Watch this on-demand webinar on the development of psychedelics. Altasciences’ experts, Dr. Setnik and Dr. Milovan, provide an overview of the pragmatic and cost-effective approaches to conducting early-phase clinical trials with psychedelics, including adequate setup of the clinical pharmacology unit.
Speak with our experts to discuss your drug development needs.
You may also be interested in the following:
Webpages:
Scientific Journal: Challenges Associated with Schedule I Therapeutic Development
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.
Five Reasons to Choose Canada for Your Clinical Trials—From the Webinar Demystifying the Conduct of Clinical Trials in Canada
Canadian research facilities are becoming a popular choice for American and European sponsors, carrying out hundreds of clinical trials each year.
Get Quicker Clinical Trial Data
Accelerate Your Clinical Trials with Liquid-Filled Capsules
Liquid-filled, two-piece capsules offer countless advantages over other solid dosage forms―ease of scalability and manufacturing, faster absorption, simpler packaging, and higher product stability, to name a few.
They are also the recommended dosage form for insoluble or highly potent APIs, and are known to accelerate product development because they can be made with fewer excipients than other solid dosage forms, such as tablets.
Discover the full benefits of using liquid-filled capsules in your clinical trials, or view this infographic for a quick tutorial.
Related Resources:
- Webpage: Contract Manufacturing and Analytical Solutions
- eBook: Applications of Liquid-Filled Capsules in Drug Development
- Webinar: Manufacturing Solutions Using Liquid-Filled Capsules
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.
Accelerate Your Data with Our Co-located Clinic and Lab
Ensuring Chain of Custody from Clinic to Lab
Did you know that our Canadian clinical facility is only a 15-minute drive from our bioanalytical facility?
This two-minute video provides an overview of our workflows, optimized to ensure timely collection, processing, transport, and rapid analysis of your samples for expedited go/no-go decision-making. Altasciences’ highly trained clinical staff and lab analysts understand the time-sensitive nature of your projects. Real-time access to essential data is our top priority.
Speak with one of our experts to learn more about our solution and how we can support your program.
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services.
Have five minutes? Take a look at these:
Scratching the Surface of Dermal Testing